thalidomide has been researched along with Vascular Malformations in 16 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Vascular Malformations: A spectrum of congenital, inherited, or acquired abnormalities in BLOOD VESSELS that can adversely affect the normal blood flow in ARTERIES or VEINS. Most are congenital defects such as abnormal communications between blood vessels (fistula), shunting of arterial blood directly into veins bypassing the CAPILLARIES (arteriovenous malformations), formation of large dilated blood blood-filled vessels (cavernous angioma), and swollen capillaries (capillary telangiectases). In rare cases, vascular malformations can result from trauma or diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is an effective and safe treatment agent for GIVM and its associated bleeding." | 5.37 | The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study. ( Chen, HM; Chen, HY; Fang, JY; Gao, YJ; Ge, ZZ; Liu, WZ; Tan, HH; Xiao, SD, 2011) |
| "Thalidomide is an effective and relatively safe treatment for patients with refractory bleeding from gastrointestinal vascular malformations." | 5.15 | Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. ( Chen, HM; Chen, HY; Fang, JY; Gao, YJ; Ge, ZZ; Liu, WZ; Tan, HH; Wei, W; Xiao, SD; Xu, CH, 2011) |
| "Our findings revealed a key role for EGFL6 in SBVM pathogenesis and provided a mechanism explaining why thalidomide can cure small bowel bleeding resulting from SBVM." | 3.96 | Thalidomide targets EGFL6 to inhibit EGFL6/PAX6 axis-driven angiogenesis in small bowel vascular malformation. ( Gao, YJ; Ge, ZZ; Liang, Q; Lin, XL; Tang, CT; Tang, MY; Wu, S; Zhang, QW, 2020) |
| "Proteus syndrome is an overgrowth syndrome caused by a somatic activating mutation in AKT1." | 2.61 | Vascular malformations syndromes: an update. ( Arias-Santiago, S; Martinez-Lopez, A; Molina-Leyva, A; Montero-Vilchez, T; Salvador-Rodriguez, L; Tercedor-Sanchez, J, 2019) |
| "Thalidomide is an effective and safe treatment agent for GIVM and its associated bleeding." | 1.37 | The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study. ( Chen, HM; Chen, HY; Fang, JY; Gao, YJ; Ge, ZZ; Liu, WZ; Tan, HH; Xiao, SD, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Martinez-Lopez, A | 1 |
| Salvador-Rodriguez, L | 1 |
| Montero-Vilchez, T | 1 |
| Molina-Leyva, A | 1 |
| Tercedor-Sanchez, J | 1 |
| Arias-Santiago, S | 1 |
| Tang, CT | 1 |
| Zhang, QW | 1 |
| Wu, S | 1 |
| Tang, MY | 1 |
| Liang, Q | 1 |
| Lin, XL | 1 |
| Gao, YJ | 5 |
| Ge, ZZ | 5 |
| Weinrich, JM | 1 |
| Beyer, R | 1 |
| Well, L | 1 |
| Tahir, E | 1 |
| Lindemann, M | 1 |
| Wilke, U | 1 |
| Adam, G | 1 |
| Bannas, P | 1 |
| Lund, GK | 1 |
| Feng, Q | 2 |
| Tan, HH | 4 |
| Chen, HM | 4 |
| Xiao, SD | 4 |
| Bauditz, J | 3 |
| Feng, N | 2 |
| Chen, H | 3 |
| Fu, S | 2 |
| Bian, Z | 1 |
| Lin, X | 1 |
| Yang, L | 1 |
| Gao, Y | 2 |
| Fang, J | 2 |
| Ge, Z | 2 |
| Zhao, Y | 1 |
| Xue, H | 1 |
| Zhang, Y | 1 |
| Li, X | 1 |
| Dai, J | 1 |
| Trenor, CC | 1 |
| Nau, JY | 1 |
| Liu, WZ | 2 |
| Xu, CH | 1 |
| Chen, HY | 2 |
| Wei, W | 1 |
| Fang, JY | 3 |
| Garrido Serrano, A | 1 |
| León, R | 1 |
| Sayago, M | 1 |
| Márquez, JL | 1 |
| Gerson, LB | 1 |
| Jackson, C | 1 |
| Lochs, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Efficacy of Thalidomide for Refractory Small Intestinal Bleeding From Vascular Malformation[NCT02707484] | Phase 3 | 150 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| The Study of the Optimal Treatment Strategy for Patients With Gastrointestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Randomized, Double Blind, Placebo Controlled Study[NCT02301949] | Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for thalidomide and Vascular Malformations
| Article | Year |
|---|---|
Vascular malformations syndromes: an update.
Topics: Abnormalities, Multiple; Bevacizumab; Class I Phosphatidylinositol 3-Kinases; Growth Disorders; Huma | 2019 |
Effective treatment of gastrointestinal bleeding with thalidomide--Chances and limitations.
Topics: Angiogenesis Inhibitors; Animals; Gastrointestinal Hemorrhage; Humans; Risk Factors; Thalidomide; Tr | 2016 |
Medical management of vascular anomalies.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Bevacizumab; Clinical Decision-Making; Drug Th | 2016 |
Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Thalidomide; Vascular | 2007 |
1 trial available for thalidomide and Vascular Malformations
| Article | Year |
|---|---|
Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; G | 2011 |
Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; G | 2011 |
Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; G | 2011 |
Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; G | 2011 |
11 other studies available for thalidomide and Vascular Malformations
| Article | Year |
|---|---|
Thalidomide targets EGFL6 to inhibit EGFL6/PAX6 axis-driven angiogenesis in small bowel vascular malformation.
Topics: Angiogenesis Inhibitors; Animals; Calcium-Binding Proteins; Cell Adhesion Molecules; Cycloheximide; | 2020 |
Assessment of Congenital Vascular and Organ Anomalies in Subjects With Thalidomide Embryopathy Using Non-Contrast Magnetic Resonance Angiography.
Topics: Congenital Abnormalities; Creatinine; Female; Fetal Diseases; Gallbladder; Glomerular Filtration Rat | 2018 |
Thalidomide-induced angiopoietin 2, Notch1 and Dll4 downregulation under hypoxic condition in tissues with gastrointestinal vascular malformation and human umbilical vein endothelial cells.
Topics: Adult; Aged; Angiogenesis Inhibitors; Angiopoietin-2; Cell Division; Cell Hypoxia; Cells, Cultured; | 2014 |
[Effectiveness and security of thalidomide for gastrointestinal bleeding and severe Crohn's disease in children].
Topics: Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Immunosuppressi | 2014 |
HIF-1α and HIF-2α induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Animals; Basic Helix-Loo | 2016 |
Bleeding recurrence in patients with gastrointestinal vascular malformation after thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Gastro | 2016 |
[Thalidomide: new therapeutic indications?].
Topics: Angiogenesis Inhibitors; Humans; Leprostatic Agents; Leprosy, Lepromatous; Telangiectasia, Hereditar | 2010 |
The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study.
Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-2; Calcium-Binding Proteins; Gastrointestinal Hem | 2011 |
Thalidomide treatment in cirrhotic patients with severe anemia secondary to vascular malformations.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; | 2012 |
[The potential pathogenesis of gastrointestinal vascular malformation and the potential mechanism of thalidomide in the treatment of gastrointestinal vascular malformation].
Topics: Adult; Aged; Angiopoietin-2; Female; Gastrointestinal Tract; Gene Expression Regulation; Human Umbil | 2012 |
Time to consider medical therapy for small-bowel angioectasias.
Topics: Gastrointestinal Agents; Humans; Intestinal Diseases; Intestine, Small; Octreotide; Thalidomide; Vas | 2012 |